CANCAP02: A study into the pharmacodynamic biomarker effects of vistusertib (AZD2014), an mTORC1/2 inhibitor, given prior to radical prostatectomy (RP).

被引：0
|
作者：
Pacey, Simon
Corbacho, Javier Garcia
Shah, Nimish
Brat, Ola
Warren, Anne
Baird, Richard D.
机构：
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2017年 / 35卷 / 06期
关键词：
D O I：
10.1200/JCO.2017.35.6_suppl.97
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
97
引用
收藏
页数：2
相关论文
共 31 条
  • [1] A pharmacodynamic biomarker study of vistusertib (AZD2014), an mTORC1/2 inhibitor, given prior to radical prostatectomy (CANCAP02).
    Pacey, Simon
    Shah, Nimish
    Davies, Barry
    Bratt, Ola
    Warren, Anne
    Baird, Richard D.
    Gnanapragasam, Vincent
    Ingle, Susan
    Stearn, Sara
    Machin, Andrea
    Qian, Wendi
    Zhao, Wanfeng
    Harrington, Elizabeth
    Oelmann, Elisabeth Maria
    Hategan, Mirela
    Kumar, Sanjeev Srinivas
    Corbacho, Javier Garcia
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [2] A study into the pharmacodynamic biomarker effects of olaparib (PARP Inhibitor) degarelix (GnRH antagonist) given prior to radical prostatectomy (RP) CANCAP03.
    Pacey, Simon
    Linch, Mark David
    Kynaston, Howard
    Warren, Anne
    Freeman, Alex
    Tysoe, Ruth
    Shaw, Greg
    Narahari, Krishna
    Kumar, Satish
    Martin, Henno
    Kularatne, Bihani
    Gnanapragasam, Vincent
    Davies, Barry
    Khan, Josephine
    Bratt, Ola
    Dev, Harveer
    Massie, Charles
    Shah, Nimish
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (07)
  • [3] Dramatic antitumor effects of the dual mTORC1 and mTORC2 inhibitor AZD2014 in hepatocellular carcinoma
    Liao, Hui
    Huang, Yu
    Guo, Botang
    Liang, Bo
    Liu, Xincheng
    Ou, Huohui
    Jiang, Chenglong
    Li, Xianghong
    Yang, Dinghua
    AMERICAN JOURNAL OF CANCER RESEARCH, 2015, 5 (01): : 125 - 139
  • [4] The mTORC1 inhibitor rapamycin and the mTORC1/2 inhibitor AZD2014 impair the consolidation and persistence of contextual fear memory
    Phillip E. MacCallum
    Jacqueline Blundell
    Psychopharmacology, 2020, 237 : 2795 - 2808
  • [5] The mTORC1 inhibitor rapamycin and the mTORC1/2 inhibitor AZD2014 impair the consolidation and persistence of contextual fear memory
    MacCallum, Phillip E.
    Blundell, Jacqueline
    PSYCHOPHARMACOLOGY, 2020, 237 (09) : 2795 - 2808
  • [6] Updated analysis of "CANCAP03" - A study into the pharmacodynamic biomarker effects of olaparib (PARP inhibitor) ± degarelix (GnRH antagonist) given prior to radical prostatectomy
    Dev, Harveer
    Linch, Mark
    Kynaston, Howard
    Shaw, Greg
    Narahari, Krishna
    Hernandez, Tatiana
    Warren, Anne
    Malaviya, Alopa
    Harrington, Elizabeth
    Glont, Silvia
    Sqautrito, Massimo
    Armenia, Joshua
    Moore, Luiza
    Hanson, Robert
    Milne-Clarke, Toby
    Anand, Shubha
    Massie, Charlie
    Shah, Nimish
    Pacey, Simon
    CANCER RESEARCH, 2023, 83 (11)
  • [7] The mTORC1/mTORC2 inhibitor AZD2014 enhances the radiosensitivity of glioblastoma stem-like cells
    Kahn, Jenna
    Hayman, Thomas J.
    Jamal, Muhammad
    Rath, Barbara H.
    Kramp, Tamalee
    Camphausen, Kevin
    Tofilon, Philip J.
    NEURO-ONCOLOGY, 2014, 16 (01) : 29 - 37
  • [8] The combination of the dual mTORC1/mTORC2 inhibitor AZD2014 and paclitaxel in human ovarian cancer models
    Stewart, Adam
    Thavasu, Parames
    Heaton, Simon
    Banerjee, Susana
    Kaye, Stan B.
    Banerji, Udai
    CANCER RESEARCH, 2012, 72
  • [9] The mTORC1/mTORC2 Inhibitor AZD2014 Enhances the Radiosensitivity of Glioblastoma Stem-like Cells
    Kahn, J.
    Hayman, T. J.
    Camphausen, K.
    Tofilon, P. J.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2012, 84 (03): : S697 - S697
  • [10] AZD2014, a dual mTORC1 and mTORC2 inhibitor is differentiated from allosteric inhibitors of mTORC1 in ER+ breast cancer
    Guichard, Sylvie M.
    Howard, Zoe
    Heathcote, Dan
    Roth, Mark
    Hughes, Gareth
    Curwen, Jon
    Yates, James
    Logie, Armelle
    Holt, Sarah
    Chresta, Christine M.
    Davies, Barry R.
    Malagu, Karine
    Hummersone, Marc
    Pass, Sarah L.
    Green, Stephen
    Pass, Martin
    CANCER RESEARCH, 2012, 72
1234